Flash Finance

Innova Captab LimitedINNOVACAPCorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Jun 2026 14 quarters of data
Consolidated Standalone
₹1,019.80
MCap ₹5,836 Cr · P/E 11.7
Innova Captab Limited — Stock analysis & AI research Innova Captab Limited — Multibagger AI analysis Innova Captab Limited — Seasonality — best & worst months Innova Captab Limited — Technical indicators & charts Innova Captab Limited — Technical setup — score, trend, support & resistance Innova Captab Limited — Live exchange announcements
📋 High ROE Stocks📋 High Interest Coverage Stocks📋 Low P/E Stocks📋 Stocks Cheaper Than Their Industry📋 High Profit Growth Stocks📋 Stocks With Strong Quarterly Results 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹471 Cr
Sales · Jun 2026
+33.9% YoY
₹73 Cr
Operating Profit · Jun 2026
+40.3% YoY
15.5%
OPM % · Jun 2026
+4.7% YoY
₹44 Cr
Net Profit · Jun 2026
+42.3% YoY
₹7.71
EPS · Jun 2026
+42.3% YoY

📝 Innova Captab Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Innova Captab Limited reported revenue of ₹471 crore for the quarter ended June 2026 (Q1 FY27), up 33.9% from ₹352 crore in the same quarter last year, and down 89.5% sequentially over the March 2026 quarter.

Net profit rose 42.3% year-on-year to ₹44 crore, from ₹31 crore. Earnings per share (EPS) came in at ₹7.71.

Operating profit stood at ₹73 crore — an operating margin (OPM) of 15.5%, compared with 14.8% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Innova Captab Limited posted revenue of ₹5,660 crore, a growth of 355.1% over FY25, with a net profit of ₹484 crore (up 277.4% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹5,779 crore with a net profit of ₹497 crore.

Valuation snapshot

At the current price of ₹1,019.80, INNOVACAP has a market capitalisation of ₹5,836 crore and a trailing P/E of about 11.7.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 6th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 50.90%, foreign institutional investors (FIIs) 0.84%, domestic institutional investors (DIIs) 19.16%, public shareholders 29.09% of Innova Captab Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹5,836 Cr
Current Price ?
₹1,019.8
P/E ?
11.74below ind
Industry P/E ?
37.20
P/B ?
5.35
P/S ?
1.01
P/FCF ?
106.11
Enterprise Value ?
₹6,180 Cr
EV/EBITDA ?
7.31
PEG ?
0.42
Earnings Yield ?
11.1%
Dividend Yield ?
0.20%
Profitability & Returns
Sales (TTM) ?
₹5,779 Cr
OPM ?
14.6%
Profit after tax (TTM) ?
₹497 Cr
EPS (TTM) ?
₹86.87
ROCE ?
15.0%
ROE ?
45.6%
ROA ?
27.1%
Growth
Sales — latest qtr ?
₹471 Cr
PAT — latest qtr ?
₹44 Cr
YoY qtr sales growth ?
33.9%
YoY qtr profit growth ?
42.3%
Sales growth (3y) ?
21%
Sales growth (5y) ?
32%
Profit growth (3y) ?
28%
Profit growth (5y) ?
32%
Financial Health
Debt ?
₹344 Cr
Debt to Equity ?
0.32
Interest Coverage ?
10.9
Current Ratio ?
N/A
Ownership
Promoter holding ?
50.90%
Change in promoter holding ?
0.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
5.9%
Return 6 months ?
37.4%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 2412332833022632943183163153523804504,478471 +33.9% -89.5%
Operating Profit 27314045384250474852526965173 +40.3% -88.8%
Other Income 313262243422162 -55.2% -87.2%
Interest 559710002384464 +54.9% -90.4%
Depreciation 335535551011221111412 +6.0% -89.7%
Profit Before Tax 21253035403947463943825650759 +38.2% -88.4%
Net Profit 17182325292935343031304238144 +42.3% -88.4%
EPS 3.593.664.774.395.025.156.125.975.175.425.187.376.657.71 +42.3% +15.9%
OPM % 11.2% 13.3% 14.1% 14.7% 14.5% 14.3% 15.6% 14.7% 15.2% 14.8% 13.7% 15.4% 14.5% 15.5% +4.7% +6.9%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹1,244 Cr ₹5,660 Cr ₹5,779 Cr +355.1%
Operating Profit ₹186 Cr ₹824 Cr ₹845 Cr +342.9%
OPM % 14.97% 14.57% 14.63% -2.7%
NPM % 10.31% 8.55% 8.60% -17.1%
Other Income ₹12 Cr ₹24 Cr ₹21 Cr +98.1%
Depreciation ₹25 Cr ₹159 Cr ₹159 Cr +540.5%
Interest ₹2 Cr ₹61 Cr ₹63 Cr +2436.8%
EBIT ₹161 Cr ₹666 Cr ₹686 Cr +312.5%
PBT ₹171 Cr ₹687 Cr ₹703 Cr +301.7%
Tax ₹43 Cr ₹151 Cr ₹154 Cr +253.4%
Net Profit ₹128 Cr ₹484 Cr ₹497 Cr +277.4%
EPS ₹22.41 ₹24.62 ₹26.91 +9.9%
Material Cost ₹839 Cr ₹3,469 Cr ₹3,554 Cr +313.4%
Employee Cost ₹117 Cr ₹509 Cr ₹515 Cr +335.9%
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 48575757 +0.0%
Reserves 2297749021,034 +14.6%
Borrowings 237245338344 +1.8%
Other Liabilities 191240271401 +48.0%
Total Liabilities 7041,3161,5681,836 +17.1%
Fixed Assets 183358830842 +1.4%
CWIP 223412316 -30.4%
Investments 00041 —
Other Assets 500617716938 +31.0%
Total Assets 7041,3161,5681,836 +17.1%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 6714664117 +82.8%
Cash from Investing Activity -91-499-152-107 +29.6%
Cash from Financing Activity 2736192-22 -123.9%
Net Cash Flow 384-12 -400.0%
Free Cash Flow -11-141-10855 +150.9%
CFO/OP 76%113%47%59% +25.5%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 104979798 +1.0%
Inventory Days 7791119125 +5.0%
Days Payable 105113115141 +22.6%
Cash Conversion Cycle 777510182 -18.8%
Working Capital Days 58778186 +6.2%
ROCE % 24%19%15%15% +0.0%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Sep 2026 % Chg
Promoters 50.90%50.90%50.90%50.90%50.90% +0.0%
FIIs 0.23%0.08%0.10%0.23%0.84% +265.2%
DIIs 19.67%20.17%20.24%20.14%19.16% -4.9%
Public 29.20%28.86%28.76%28.74%29.09% +1.2%
No. of Shareholders 41,01440,24538,69136,96536,551 -1.1%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 AKUMS Akums Drugs ₹784.55 12,012 41.2 4,502 293 12.6% 6.5% 5.9% -25.5% 13.9% 56.1%
2 STAR Strides Pharma ₹1,085.00 10,001 26.7 3,636 389 25.4% 10.7% -20.4% 99.0% 11.2% 50.0%
3 BLUEJET Blue Jet ₹565.05 9,802 36.9 884 265 36.3% 30.0% 8.0% 0.7% -17.5% -14.3%
4 AARTIPHARM Aarti Pharmalabs ₹828.30 7,511 36.1 1,957 208 22.0% 10.6% 1.5% -26.9% 42.4% 39.2%
5 SUPRIYA Supriya Lifescience ₹870.30 7,004 35.3 873 198 33.2% 22.7% 18.9% 11.1% 30.8% -30.9%
6 INNOVACAP Innova Captab ₹1,199.30 6,863 13.8 5,779 497 14.6% 8.6% 355.1% 277.4% 33.9% 42.3%
7 MOREPENLAB Morepen Laboratories ₹123.35 6,759 48.0 1,951 141 9.4% 7.2% -0.3% -18.3% 34.1% 394.0%
8 IOLCP IOL Chemicals ₹201.19 5,905 35.2 2,523 168 12.3% 6.7% 11.5% 36.6% 37.1% 89.8%
9 FDC FDC ₹350.20 5,702 19.5 2,191 291 15.3% 13.3% 3.0% 4.8% 3.0% 9.5%
10 NOVARTIND Novartis India ₹2,257.80 5,575 57.0 371 97 27.6% 26.2% -0.3% -6.9% 18.2% 14.3%
11 ORCHPHARMA Orchid Pharma ₹1,058.75 5,370 236.9 812 22 5.1% 2.7% -11.9% -76.4% 0.2% 25.4%
12 RPGLIFE RPG Life ₹2,865.90 4,740 39.7 735 120 21.1% 16.3% 8.4% -36.9% 15.8% 16.3%
13 ZOTA Zota Health ₹1,232.70 4,269 — 609 -104 0.6% -17.1% 84.6% -29.8% 66.9% -213.9%
14 GUFICBIO Gufic Biosciences ₹419.85 4,210 57.3 974 74 16.9% 7.6% 14.7% -9.1% 14.9% 86.0%
15 UNICHEMLAB Unichem Laboratories ₹526.70 3,708 12.2 2,308 305 9.9% 13.2% 6.2% 74.1% 20.1% 496.1%
16 INDSWFTLAB Ind-Swift Laboratories ₹374.00 3,252 55.4 665 57 9.0% 8.6% 235.3% 10.1% 32.3% -88.7%
17 ADVENZYMES Advanced Enzyme ₹293.25 3,249 19.8 750 172 29.8% 22.9% 17.1% 29.6% 2.1% -4.6%
18 SOLARA Solara Active ₹667.00 3,218 85.6 1,535 37 15.2% 2.4% 6.6% -1470.4% 33.1% 381.8%
19 DCAL Dishman Carbogen ₹162.08 2,541 157.6 2,902 16 16.7% 0.6% 8.1% 2655.7% -4.3% -351.7%
20 INDOCO Indoco Remedies ₹254.59 2,347 n/m 1,872 3 8.8% 0.2% 10.7% -26.5% 6.5% 280.0%
21 PANACEABIO Panacea Biotec ₹368.55 2,257 — 673 -9 0.3% -1.3% 14.4% 17.9% 19.7% -44.4%
22 REMUS Remus Pharma. ₹1,911.30 2,252 91.1 94 25 31.7% 26.7% — — 13.3% 21.4%
23 SAKAR Sakar Healthcare ₹987.40 2,167 61.0 272 36 28.5% 13.3% 41.9% 71.8% 38.4% 120.2%
24 JAGSNPHARM Jagsonpal Pharmaceuticals ₹227.53 1,501 33.3 294 45 20.7% 15.4% 6.9% -22.2% 8.5% 20.4%
25 KOPRAN Kopran ₹281.55 1,361 54.5 700 25 8.7% 3.6% -96.0% -97.6% 13.9% -10.0%
❓ Frequently asked questions
What was Innova Captab Limited's revenue in Q1 FY27?
Innova Captab Limited reported revenue of ₹471 crore for the quarter ended June 2026 (Q1 FY27), up 33.9% from ₹352 crore in the same quarter last year, and down 89.5% sequentially over the March 2026 quarter.
What was Innova Captab Limited's net profit in Q1 FY27?
Net profit rose 42.3% year-on-year to ₹44 crore, from ₹31 crore. Earnings per share (EPS) came in at ₹7.71.
What is INNOVACAP's market capitalisation and P/E ratio?
At the current price of ₹1,019.80, INNOVACAP has a market capitalisation of ₹5,836 crore and a trailing P/E of about 11.7.
Who owns Innova Captab Limited? (shareholding pattern)
As of Sep 2026, promoters held 50.90%, foreign institutional investors (FIIs) 0.84%, domestic institutional investors (DIIs) 19.16%, public shareholders 29.09% of Innova Captab Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI